AMAG's anaemia drug Feraheme escapes FDA black box warning
This article was originally published in Scrip
Executive Summary
Shares in AMAG Pharmaceuticals rose by 13% on 29 November after the company revealed that the updated label it agreed to with the US FDA for its lead anaemia drug Feraheme (ferumoxytol) would not require the agency's most stringent black box warning.